Pharma News, 2026

Roche drops Phase III development of anti-myostatin antibody emugrobart for FSHD and SMA due to lack of efficacy, while shifting focus to obesity trials.

Arvinas announces encouraging phase 1 data for its PROTAC degrader ARV-102, showing over 50% LRRK2 degradation in Parkinson's disease patients' CSF.

The FDA issued a Complete Response Letter to Aldeyra Therapeutics for its reproxalap NDA to treat dry eye disease, citing a lack of efficacy evidence.

Nia Therapeutics' Smart Neurostimulation System receives FDA breakthrough designation to treat episodic memory loss in adults with traumatic brain injury.

Hoth Therapeutics is leveraging AI to advance its targeted antisense oligonucleotide HT-KIT for KIT-driven cancers toward IND submission and Phase I trials.

Researchers engineered probiotic bacteria to deliver anti-cancer drugs directly to tumors, showing promising targeted therapy results in preclinical models.

AstraZeneca's Imfinzi, combined with FLOT chemotherapy, receives EU approval for treating adult patients with resectable early gastric and GEJ cancers.

Argo Biopharma receives FDA Fast Track Designation for BW-20805, a novel siRNA therapy targeting PKK for the prevention of hereditary angioedema attacks.

UCLA researchers developed an off-the-shelf CAR-NKT immunotherapy that safely detects and destroys aggressive endometrial cancer in preclinical studies.

Peking University's cf-EpiTracing liquid biopsy platform detects and traces diseases, like cancer, from a single drop of blood with over 92% accuracy.

BITS Pilani researchers develop a smart nanomedicine-based topical gel showing promising preclinical results for rheumatoid arthritis treatment and relief.

Parkinson's disease research hits a pivotal point with new iPSC models, yet funding challenges and outdated trials slow development.